These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2748880)

  • 1. Consequences of monoamine oxidase inhibition: increased vesicular accumulation of dopamine and norepinephrine and increased metabolism by catechol-O-methyltransferase and phenolsulfotransferase.
    Buu NT; Lussier C
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(3-4):563-8. PubMed ID: 2748880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between catechol-O-methyltransferase and phenolsulfotransferase in the metabolism of dopamine in the rat brain.
    Buu NT
    J Neurochem; 1985 Nov; 45(5):1612-9. PubMed ID: 3930664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of dopamine and norepinephrine metabolism in the rat brain by monoamine oxidase inhibitors.
    Buu NT; Angers M; Duhaime J; Kuchel O
    J Neural Transm; 1987; 70(1-2):39-50. PubMed ID: 3668521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of different monoamine oxidase inhibitors on the metabolism of L-dopa in the rat brain.
    Nguyen TB; Angers M
    Biochem Pharmacol; 1987 May; 36(10):1731-5. PubMed ID: 3109430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vesicular accumulation of dopamine following L-DOPA administration.
    Buu NT
    Biochem Pharmacol; 1989 Jun; 38(11):1787-92. PubMed ID: 2735936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of vesicular dopamine and norepinephrine by monoamine oxidase inhibitors.
    Buu NT
    Biochem Pharmacol; 1989 May; 38(10):1685-92. PubMed ID: 2730683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Handling of dopamine and dopamine sulfate by isolated perfused rat kidney.
    Buu NT; Duhaime J; Kuchel O
    Am J Physiol; 1986 Jun; 250(6 Pt 2):F975-9. PubMed ID: 3717353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat.
    Männistö PT; Tuomainen P
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct; 344(4):412-8. PubMed ID: 1766471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-dopa metabolism in genetically hypertensive mice: effect of pargyline.
    Buu NT; Duhaime J; Racz K; Kuchel O; Schlager G
    Can J Physiol Pharmacol; 1987 Dec; 65(12):2390-5. PubMed ID: 3449195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of short and long-lasting effects of pargyline on cerebral dopamine metabolism.
    Waldmeier PC; Maître L
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Aug; 294(2):133-40. PubMed ID: 1012333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The contribution by monoamine oxidase and catechol-O-methyltransferase to the total-body and pulmonary plasma clearance of catecholamines.
    Friedgen B; Wölfel R; Graefe KH
    Naunyn Schmiedebergs Arch Pharmacol; 1996 Jan; 353(2):193-9. PubMed ID: 8717160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of sulfate conjugation, deamination, and O-methylation to metabolism of dopamine and norepinephrine in human brain.
    Rivett AJ; Eddy BJ; Roth JA
    J Neurochem; 1982 Oct; 39(4):1009-16. PubMed ID: 6956674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-Methoxytyramine and normetanephrine as indicators of dopamine and noradrenaline release in mouse brain in vivo.
    Kehr W
    J Neural Transm; 1981; 50(2-4):165-78. PubMed ID: 7241115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-Methoxytyramine formation following monoamine oxidase inhibition is a poor index of dendritic dopamine release in the substantia nigra.
    Elverfors A; Pileblad E; Lagerkvist S; Bergquist F; Jonason J; Nissbrandt H
    J Neurochem; 1997 Oct; 69(4):1684-92. PubMed ID: 9326297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of centrally released noradrenaline by extraneuronal monoamine oxidase and catechol-O-methyltransferase.
    Van Wijk M; Korf J
    Brain Res; 1976 Apr; 106(2):403-6. PubMed ID: 1276880
    [No Abstract]   [Full Text] [Related]  

  • 16. A new and highly sensitive method for measuring 3-methoxytyramine using HPLC with electrochemical detection. Studies with drugs which alter dopamine metabolism in the brain.
    Heal DJ; Frankland AT; Buckett WR
    Neuropharmacology; 1990 Dec; 29(12):1141-50. PubMed ID: 2293058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
    Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
    Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of effect of corticotropin releasing factor on hypothalamic dopamine and serotonin synthesis turnover rates in rats.
    Van Loon GR; Shum A; Ho D
    Peptides; 1982; 3(5):799-803. PubMed ID: 6294636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the acute and long-term changes in dopamine and noradrenaline metabolism in mouse brain following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Pileblad E; Carlsson A
    Pharmacol Toxicol; 1988 Apr; 62(4):213-22. PubMed ID: 3260379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vesicular and ganglionic norepinephrine in the rat: progressive increase with age.
    Buu NT; Debinski W
    J Neurochem; 1990 Feb; 54(2):620-6. PubMed ID: 2299355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.